'Terrifying': Why U.S. senator in top intel post wants more spying on Chinese companies

In a striking revelation, Democratic Senator Mark Warner from Virginia, who serves as the leading Democrat on the Senate Select Committee on Intelligence, has raised alarms about the rapid ascent of the Chinese genomics company BGI. He predicts that BGI could surpass Huawei in terms of both scale and implications for national security. While Huawei became synonymous with concerns over telecommunications security, BGI is focused on a different frontier: genetic data collection. At a recent summit, Warner stated, "If Huawei was big, BGI will be even bigger," highlighting the potential risks associated with BGI's operations in the U.S. and globally. The company, originally known as the Beijing Genomics Institute, has evolved into a major player in the genomics sector, providing DNA sequencing services for hospitals and research institutions worldwide. BGI's operations extend beyond China, having established a presence in the U.S., Europe, and Japan. This global footprint has led U.S. intelligence officials to believe that BGI possesses one of the largest collections of genetic data, which poses new strategic challenges. Warner emphasized that genetic data is not merely medical information; it is an asset that could fuel a "DNA arms race." This data, when integrated with artificial intelligence, could enable surveillance and long-term biological research that raises national security concerns. Warner's comments at the CNBC CFO Council Summit have intensified calls for increased scrutiny of BGI. He expressed concern over the company's extensive DNA data collection, stating, "They are hoovering up DNA data. This level of experimentation on humans and intellectual property theft should alarm us all." Congressional investigations have revealed BGI's close ties to the Chinese Communist Party and military, further exacerbating fears of misuse of genetic information. The potential implications of BGI's activities are stark. U.S. officials have warned of the possibility of genetically enhanced soldiers, a topic that has been publicly addressed by various government representatives. Warner's description of the situation as "terrifying" underscores the urgency of addressing these emerging threats. He noted that the rise of BGI mirrors the trajectory of Huawei, which leveraged state support and aggressive pricing to dominate the telecommunications market before the U.S. fully recognized the security implications. Now, as BGI grows rapidly with similar backing, Warner and other lawmakers are pushing for legislative measures to restrict its access to U.S. markets. Despite BGI's assurances that it complies with regulations and does not access Americans' personal data, the call for caution remains strong. Warner pointed out that U.S. intelligence has been slow to adapt to the biotech challenge, traditionally focusing more on foreign militaries than on commercial technology sectors. He believes it's crucial for intelligence efforts to evolve in response to the changing landscape of technology and national security threats. As the U.S. grapples with its position in the global technology race, the call for a proactive approach in monitoring and regulating foreign companies like BGI is becoming increasingly urgent. Warner’s remarks highlight the need for collaborative international strategies to counter threats and maintain the U.S.'s technological edge.